Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10493MR)

This product GTTS-WQ10493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10493MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5630MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ11467MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ2953MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ5305MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ13233MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ3800MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ14031MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ12757MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-52M51
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW